Losartan for EB: First steps have been taken

The EB World Congress will take place in London, UK, from 19 to 23 January 2020. Midas Pharma will attend the event to present a project that is close to the hearts of all participants and to promote the recruitment of further network partners. Learn more in our exposé!

EB Worldcongress 2020
Click here for the website: EB Worldcongress 2020

For this project, Midas is acting as an industrial partner of the University Dermatology Clinic in Freiburg, the German centre for patients with Epidermolysis Bullosa (EB), a rare disease that occurs in newborns and causes great suffering for the young patients and their parents.

As sponsor for the pharmaceutical development of a paediatric dosage form of Losartan we will present a poster on the congress as co-authors.

Drug development requires a huge effort, even with an ‘easy’ development path. The first steps have been made. The project is advancing. But to reach maturity more capacity is needed and so the recruitment efforts for additional network partners are ongoing.

Funding is needed to conduct the Phase III clinical trial REFLECT 2 and to develop the respective study medication of losartan.

Further information about the project can be found in this exposé. Please feel free to contact us with any questions at any time.

Your Contact

Prof. Dr.  Sigrid Saaler-Reinhardt

Prof. Dr. Sigrid Saaler-Reinhardt

Biotechnology & Combination Products
Senior Director

Midas Pharma GmbH
Rheinstr. 49
55218 Ingelheim
Send E-Mail

Share this page